Lba41 - Leap-005: Phase Ii Study Of Lenvatinib Plus Pembrolizumab

LBA41 - LEAP-005: Phase II study of lenvatinib plus pembrolizumab

ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005

European Society for Medical Oncology (ESMO)

Promising results from the gastric cancer cohort of LEAP-005

LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma

Dr. Lwin on the Results of the LEAP-005 Trial in Advanced Solid Tumors

Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer

Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor...

NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

LBA44 - Lenvatinib plus pembrolizumab for advanced melanoma

#ESMO19: Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer

Society of Gynecologic Oncology

What is LEAP?

Axion BioSystems

Alpelisib and T-DM1 for HER2-Positive Metastatic Breast Cancer

KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients

LEAP-012 from ESMO 2024 - Pembrolizumab + Lenvatinib Added to TACE Improved PFS in HCC

Oncology Brothers Clips

KEYNOTE-775 subgroup analysis in advanced endometrial cancer

KEYSTEP-004: combination immunotherapy with lenvatinib for advanced HCC

Sequencing endocrine treatment in metastatic luminal breast cancer and alpelisib for treatment o...

Study of Nab-Paclitaxel with Pembrolizumab for Patients with HR+/HER2- Breast Cancer

Dana-Farber Cancer Institute

AML Studies: BiTE Antibodies and Age for Transplant